Novo Nordisk A/S $NVO Shares Sold by Comgest Global Investors S.A.S.

Comgest Global Investors S.A.S. lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 63.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,961 shares of the company’s stock after selling 25,801 shares during the period. Comgest Global Investors S.A.S.’s holdings in Novo Nordisk A/S were worth $830,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in NVO. True Wealth Design LLC lifted its stake in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the period. NewSquare Capital LLC increased its holdings in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares in the last quarter. Guerra Advisors Inc acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $25,000. Strengthening Families & Communities LLC purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $30,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $49.26 on Thursday. The company has a 50-day simple moving average of $53.86 and a 200-day simple moving average of $53.24. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company has a market cap of $219.94 billion, a PE ratio of 14.20 and a beta of 0.67. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NVO. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective for the company. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $56.07.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.